A 2 minute assessment to get a personalized mental health or alcohol recovery plan.
With more medications for alcohol use disorder than ever before, it’s important to compare the options carefully. Patients can use this resource to see how traditional AUD medications like naltrexone and acamprosate compare to the new GLP-1 semaglutide meds.
What You’ll Learn:
- The three medications have been approved for alcohol use and how they work.
- The mechanistic differences for GLP-1 receptor agonists.
- A direct comparison of AUD medications.
There are three primary medications for alcohol use treatment - naltrexone, acamprosate and disulfiram - but GLP-1 semaglutide medication is now joining the list as more clinical trials show it can be beneficial. However, the mechanisms that are involved differ among the medications as well as their effectiveness.
How Traditional Alcohol Use Disorder Medications Work
Let’s start by taking a closer look at the medications that have been prescribed for treating alcohol use. While the goal is the same with all three, they work in different ways.
Naltrexone
To date, naltrexone is considered the gold standard for AUD treatment medication. It’s also the medication that is typically used for The Sinclair Method.
Naltrexone medication works by blocking opioid receptors in the brain that are involved in the reward/pleasure system that’s triggered by alcohol, particularly mu receptors. This blunts the reinforcing “high” from drinking and that in turn can reduce cravings and heavy drinking. Essentially, the positive association that’s felt from drinking is significantly blunted.
But it’s not just a feeling. It’s been proven effective at reducing heavy drinking and alcohol cravings through clinical studies, which is why it’s often considered a first-line AUD pharmacotherapy.
Acamprosate
It’s believed that acamprosate modulates the glutamate/GABA balance in the brain after chronic alcohol exposure. This reduces protracted withdrawal symptoms and supports abstinence.
Because of the way it works, acamprosate is best for people who are already abstinent or in withdrawal and wanting to get past that hurdle.
Disulfiram
Disulfiram takes a dramatically different approach to getting people to stop drinking. It blocks aldehyde dehydrogenase, which causes an accumulation of acetaldehyde when alcohol is consumed. The accumulation leads to very unpleasant symptoms if someone drinks.
So, disulfiram is considered a deterrent, not a craving reducing agent. It motivates people to stop drinking by way of avoidance.
The Mechanistic Differences For GLP-1 Receptor Agonists
GLP-1 semaglutide medication has some key similarities and differences from the medications above. GLP-1 receptor agonists were developed for diabetes and obesity, but evidence suggests they may also modulate reward and motivation pathways that relate to alcohol use.
GLP-1 receptors are expressed in brain regions tied to reward and motivation, such as the mesolimbic dopamine system. Activation of these receptors have the potential to dampen the rewarding effects of alcohol and reduce alcohol cravings. This differs from naltrexone, which blocks opioid receptors directly tied to alcohol’s rewarding effects, rather than modulating broader motivational circuits.
Broader Neurobehavioral Effects
GLP-1RAs may also affect stress responses, cognitive control and satiety. These are all pathways that are beginning to be connected with both eating and addiction behaviors. It’s another point that differentiates semaglutide because traditional AUD drugs do not directly influence satiety or metabolic regulation.
The Gut-Brain Effect - It’s Stronger Than We Realized
GLP-1RAs are incretin mimetics. That means they slow gastric emptying, increase fullness and improve glucose regulation. This interaction is unique from other AUD medications and may indirectly influence alcohol intake patterns.
GLP-1RAs might reduce the quantity and intensity of drinking even if abstinence isn’t the goal, meaning that like naltrexone it has a “passive harm-reduction” effect. In contrast, acamprosate’s main role is supporting abstinence maintenance, not necessarily reducing heavy drinking episodes.
The potential novel mechanisms of GLP-1 receptor agonists that span reward circuitry, metabolism, stress and cognitive systems could complement or expand what current AUD meds offer. Instead of working on specific neurotransmitter systems tied to alcohol effects or withdrawal, GLP-1RAs tap into broader brain–body integration systems, offering other health benefits in cases where traditional meds don’t.
Semagultide is Promising, But Research is Ongoing
Something to note is that the findings for semaglutide are mostly observational at the moment and not from randomized clinical trials. The results may be influenced by underlying differences in people prescribed GLP-1RAs versus other medications since GLP-1s weren’t being used expressly for alcohol use.
Randomized clinical trials are limited, but a small clinical trial with semaglutide showed reduced alcohol craving and drinking levels compared to placebo in people with AUD. Observational findings have centered on semaglutide reducing alcohol-related hospitalizations.
Comparison of AUD Medications
If you are interested in knowing more about GLP-1 or naltrexone prescription medication start by taking the Alcohol Use Assessment. The quick survey will examine behaviors around drinking and provide recommendations on how to meet your goals and make improvements.
Key Takeaways
- GLP-1RAs operate via different neurobiological pathways by modulating reward, stress and metabolic signals rather than just blocking alcohol reward signals or managing withdrawal.
- Existing AUD treatments remain important and are FDA-approved with known efficacy.
- Early evidence suggests GLP-1RAs could reduce heavy drinking and cravings, potentially more than traditional meds in some populations, but randomized clinical trials are needed to confirm this.
- GLP-1RAs might be especially valuable as a harm-reduction tool even if full abstinence isn’t the goal.
